High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma

被引：0
|
作者：
Quan, WDY
Taylor, WC
Ramirez, M
Vinogradov, M
Khan, N
Jackson, S
机构：
[1] Univ Texas, Med Branch, Galveston, TX 77550 USA
[2] E Carolina Univ, Sch Med, Greenville, NC USA
[3] Med Coll Ohio, Div Med Oncol & Hematol, Coll Med, Toledo, OH 43699 USA
来源：
JOURNAL OF IMMUNOTHERAPY | 2004年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S5 / S6
页数：2
相关论文
共 50 条
  • [41] Should High-Dose Interleukin-2 Still Be the Preferred Treatment for Patients with Metastatic Melanoma?
    Dillman, Robert O.
    Barth, Neil M.
    VanderMolen, Louis A.
    Mahdavi, Khosrow
    McClure, Stephanie E.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2012, 27 (06) : 337 - 343
  • [42] Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma
    Legha, SS
    Gianan, MA
    Plager, C
    Eton, OE
    Papadopoulous, NEJ
    CANCER, 1996, 77 (01) : 89 - 96
  • [43] Single-institution experience of high-dose interleukin-2 therapy for metastatic melanoma
    Chu, Melinda
    Hsueh, Eddy
    Armbrecht, Eric
    Richart, John
    Fosko, Scott
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB154 - AB154
  • [44] More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma
    McDermott, David F.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3791 - 3793
  • [45] THE FEASIBILITY OF REPETITIVE COURSES OF HIGH-DOSE CONTINUOUS INTRAVENOUS-INFUSION INTERLEUKIN-2 AND SUBCUTANEOUS ALPHA-INTERFERON WITH POLYCHEMOTHERAPY IN ADVANCED MALIGNANT-MELANOMA
    FOPPOLI, M
    CITTERIO, G
    POLASTRI, D
    GUERRIERI, R
    TUMORI JOURNAL, 1995, 81 (02): : 102 - 106
  • [46] Combining a peptide vaccine with high-dose interleukin-2
    Chapman, Paul B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) : 2250 - 2251
  • [47] CARDIOMYOPATHY ASSOCIATED WITH HIGH-DOSE INTERLEUKIN-2 THERAPY
    BECK, AC
    WARD, JH
    HAMMOND, EH
    WRAY, RB
    SAMLOWSKI, WE
    WESTERN JOURNAL OF MEDICINE, 1991, 155 (03): : 293 - 296
  • [48] Guidelines for the safe administration of high-dose interleukin-2
    Schwartzentruber, DJ
    JOURNAL OF IMMUNOTHERAPY, 2001, 24 (04): : 287 - 293
  • [49] EFFECT OF LOW-DOSE BOLUS, LOW-DOSE CONTINUOUS INFUSION, AND HIGH-DOSE CONTINUOUS INFUSION INTERLEUKIN-2 ON INVIVO AND INVITRO GENERATION OF LYMPHOKINE ACTIVATED KILLER CELL-ACTIVITY
    BOLTON, JS
    CHOI, YS
    COOPER, ES
    FLAUM, MA
    LEAVITT, D
    CLINICAL RESEARCH, 1989, 37 (01): : A23 - A23
  • [50] High-Dose Interleukin-2 Followed by Temozolomide Results in Response Rates of High Quality in Metastatic Melanoma
    Fateh, Salman
    Schell, Todd
    Gingrich, Rebecca
    Neves, Rogerio
    Drabick, Joseph
    JOURNAL OF IMMUNOTHERAPY, 2009, 32 (09) : 956 - 956
12345